4.5 Article

Cellular Therapies: Yesterday, Today, and Tomorrow

Journal

STEM CELLS AND DEVELOPMENT
Volume 32, Issue 7-8, Pages 163-169

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/scd.2022.0294

Keywords

cellular therapy; hematopoietic cells; immune cells; mesenchymal cells; pluripotent cells; stem cells

Ask authors/readers for more resources

Cellular therapy involves the transfer of healthy cells into a person to correct defective functions. From 1950 to 2010, it mainly involved hematopoietic transplants for hematological disorders. From 2011 to 2023, it has grown significantly with preclinical studies and clinical trials, and is progressing towards becoming a pillar of 21st century medicine. In the future, established cellular therapy modalities will be improved and novel therapies, including iPSCs, will be introduced to clinical practice.
Cellular therapy (CT) can be defined as the transference into a person of healthy cells to correct defective functions. Yesterday (1950-2010), CT consisted mostly of hematopoietic transplants for the treatment of a variety of hematological disorders. Interestingly, during that period of time other cell types with therapeutic potential-including certain lymphoid populations and other nonhematopoietic cells-were discovered and characterized; thus, CT became a promising discipline for the treatment of a broader diversity of diseases. Today (2011-2023), CT has significantly grownup through preclinical studies and clinical trials, and it is currently progressing toward its consolidation as one of the pillars of medicine in the 21st century. Indeed, different types of stem cells (e.g., hematopoietic, mesenchymal, neural, and pluripotent), as well as different lymphoid and myeloid cell populations (e.g., TILs, CAR-Ts, CAR-NKs, and DUOC-01) are being used in clinical settings or are being tested in clinical trials. For the past decade, several CT modalities have been developed, and today, many of them are being used in the clinic. Tomorrow (2024-2040), already established CT modalities will surely be improved and applied more frequently, and novel therapies (that will include cell types such as iPSCs) will enter and expand within the clinical ground. It is noteworthy, however, that despite significant advancements and achievements, problems still need to be solved and obstacles need to be overcome. Technical, ethical, and economic issues persist and they need to be addressed. Undoubtedly, exciting times of challenges and opportunities are coming ahead in the CT arena.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available